| The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys M Stremlau, CM Owens, MJ Perron, M Kiessling, P Autissier, J Sodroski Nature 427 (6977), 848-853, 2004 | 2395 | 2004 |
| Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells CM Owens, PC Yang, H Göttlinger, J Sodroski Journal of virology 77 (1), 726-731, 2003 | 192 | 2003 |
| Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC) H Choe, MJ Moore, CM Owens, PL Wright, N Vasilieva, W Li, AP Singh, ... Molecular microbiology 55 (5), 1413-1422, 2005 | 177 | 2005 |
| Binding and susceptibility to postentry restriction factors in monkey cells are specified by distinct regions of the human immunodeficiency virus type 1 capsid CM Owens, B Song, MJ Perron, PC Yang, M Stremlau, J Sodroski Journal of virology 78 (10), 5423-5437, 2004 | 157 | 2004 |
| Compositions and methods for treatment of viral diseases LM Johansen, CM Owens, C Mawhinney, TW Chappell, AT Brown, ... US Patent App. 11/900,893, 2008 | 127 | 2008 |
| Combination pharmaceutical agents as inhibitors of HCV replication YS Or, CM Owens, BB Brasher, YL Qiu, L Jiang US Patent 9,060,971, 2015 | 63 | 2015 |
| Compositions and methods for treatment of viral diseases LM Johansen, CM Owens, C Mawhinney, TW Chappell, AT Brown, ... US Patent App. 12/406,626, 2010 | 55 | 2010 |
| Chemical combinations elucidate pathway interactions and regulation relevant to Hepatitis C replication CM Owens, C Mawhinney, JM Grenier, R Altmeyer, MS Lee, AA Borisy, ... Molecular systems biology 6 (1), 375, 2010 | 44 | 2010 |
| Methods and compositions for the treatment and prevention of HIV infection using TRIM5α J Sodroski, M Stremlau, CM Owens US Patent 7,659,382, 2010 | 27 | 2010 |
| Envelope glycoprotein determinants of increased entry in a pathogenic simian–human immunodeficiency virus (SHIV-HXBc2P 3.2) passaged in monkeys Z Si, P Gorry, G Babcock, CM Owens, M Cayabyab, N Phan, J Sodroski AIDS research and human retroviruses 20 (2), 163-173, 2004 | 18 | 2004 |
| Asymmetric titanium-catalyzed cyclopropanation of nitriles with Grignard reagents J Caillé, P Setzer, F Boeda, MSM Pearson-Long, P Bertus SynOpen 2 (01), 0041-0049, 2018 | 12 | 2018 |
| Compositions and methods for treatment of viral diseases LM Johansen, CM Owens US Patent App. 12/583,242, 2010 | 12 | 2010 |
| Preclinical profile and clinical efficacy of a novel hepatitis C virus NS5A inhibitor, EDP-239 CM Owens, BB Brasher, A Polemeropoulos, MHJ Rhodin, N McAllister, ... Antimicrobial agents and chemotherapy 60 (10), 6207-6215, 2016 | 6 | 2016 |
| CYCLOPHILIN INHIBITOR EDP-546 IS A POTENTIAL CORNERSTONE DRUG FOR USE IN COMBINATION WITH NS5A AND PROTEASE INHIBITORS DUE TO ITS HIGH BARRIER TO HCV RESISTANCE CM Owens, MHJ Rhodin, A Polemeropoulos, J Long, G Wang, L Jiang, ... JOURNAL OF HEPATOLOGY 58, S493-S493, 2013 | 6 | 2013 |
| Preclinical and clinical resistance profile of EDP-239, a novel hepatitis C virus NS5A inhibitor CM Owens, BB Brasher, A Polemeropoulos, MHJ Rhodin, N McAllister, ... Antimicrobial agents and chemotherapy 60 (10), 6216-6226, 2016 | 5 | 2016 |
| EDP-546, a Potent and Novel Cyclophilin Inhibitor with Favorable Preclinical Pharmacokinetic and Safety Profiles: 1895 L Jiang, S Liu, AJ Polemeropoulos, MH Rhodin, CM Owens, X Luo, ... Hepatology 56, 1076A, 2012 | 5 | 2012 |
| 1213 A HIGHLY POTENT HCV NS5A INHIBITOR EDP-239 WITH FAVORABLE PRECLINICAL PHARMACOKINETICS LJ Jiang, S Liu, T Phan, C Owens, B Brasher, A Polemeropoulos, X Luo, ... Journal of hepatology, S479, 2011 | 4 | 2011 |
| EP-CYP546 IS A POTENT NON-IMMUNOSUPPRESSIVE CYCLOPHILIN INHIBITOR WITH AN EXCELLENT PRECLINICAL PROFILE: 367 CM Owens, B Brasher, AJ Polemeropoulos, J Long, X Gao, YL Qiu, ... Hepatology 54 (4), 541A-542A, 2011 | 2 | 2011 |
| Treatment of herpetic keratitis with CRISPR/Cas9 gene editing in a rabbit disease model S Shen, CM Owens, H Chao, CJ Yudkoff, B Diner, R Fusco, D Tabbaa, ... MOLECULAR THERAPY 26 (5), 128-128, 2018 | 1 | 2018 |
| EDP-239, a novel HCV NS5A inhibitor, demonstrates potent antiviral activity after a single dose treatment of genotype 1 HCV patients E Lawitz, F Poordad, J Rondon, TD Box, S Zeuzem, P Buggisch, KA Wong, ... HEPATOLOGY 62, 1306A-1306A, 2015 | 1 | 2015 |
